How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?

被引：1
|
作者：
Takigawa, Nagio [1 ]
机构：
[1] Kawasaki Med Sch, Dept Gen Internal Med 4, Kita Ku, 2-6-1 Nakasange, Okayama 7008505, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
OPEN-LABEL; ACQUIRED-RESISTANCE; CRIZOTINIB; CHEMOTHERAPY; IDENTIFICATION; INHIBITION; MUTATIONS; CERITINIB;
D O I：
10.1016/j.jtho.2018.07.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1438 / 1440
页数：3
相关论文
共 50 条
  • [1] Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory
    Li, Yimeng
    Hao, Zhanpeng
    Ma, Yuyan
    Setiwalidi, Kaidiriye
    Zhang, Yingming
    Zhao, Yujia
    Fu, Xiao
    Liang, Xuan
    Ruan, Zhiping
    Tian, Tao
    Yao, Yu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (01) : 152 - 162
  • [2] How I treat ALK-positive non-small cell lung cancer
    McCusker, Michael G.
    Russo, Alessandro
    Scilla, Katherine A.
    Mehra, Ranee
    Rolfo, Christian
    ESMO OPEN, 2019, 4
  • [3] Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Ozasa, Hiroaki
    Sakamori, Yuichi
    Tsuji, Takahiro
    Nomizo, Takashi
    Yasuda, Yuto
    Yamamoto, Tomoko
    Ajimizu, Hitomi
    Hirai, Toyohiro
    IN VIVO, 2018, 32 (06): : 1587 - 1590
  • [4] Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
    Lin, Jessica J.
    Zhu, Viola W.
    Schoenfeld, Adam J.
    Yeap, Beow Y.
    Saxena, Ashish
    Ferris, Lorin A.
    Dagogo-Jack, Ibiayi
    Farago, Anna F.
    Taber, Angela
    Traynor, Anne
    Menon, Smitha
    Gainor, Justin F.
    Lennerz, Jochen K.
    Plodkowski, Andrew J.
    Digumarthy, Subba R.
    Ignatius, Sai-Hong
    Shaw, Alice T.
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1530 - 1538
  • [5] Alectinib for ALK-positive non-small-cell lung cancer
    Rossi, Antonio
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (08) : 1005 - 1013
  • [6] Alectinib for advanced ALK-positive non-small-cell lung cancer
    Ly, Ashley C.
    Olin, Jacqueline L.
    Smith, Morgan B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (08) : 515 - 522
  • [7] Future options for ALK-positive non-small cell lung cancer
    Iacono, Daniela
    Chiari, Rita
    Metro, Giulio
    Bennati, Chiara
    Bellezza, Guido
    Cenci, Matteo
    Ricciuti, Biagio
    Sidoni, Angelo
    Baglivo, Sara
    Minotti, Vincenzo
    Crino, Lucio
    LUNG CANCER, 2015, 87 (03) : 211 - 219
  • [8] Brigatinib as a treatment of ALK-positive non-small cell lung cancer
    De Carlo, Elisa
    Stanzione, Brigida
    Del Conte, Alessandro
    Revelant, Alberto
    Bearz, Alessandra
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (05): : 299 - 305
  • [9] Treating ALK-positive non-small cell lung cancer
    Ziogas, Dimitrios C.
    Tsiara, Anna
    Tsironis, Georgios
    Lykka, Maria
    Liontos, Michalis
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [10] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Dziadziuszko, Rafal
    Ahn, Jin Seok
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, M. Rita
    Bondarenko, Igor
    Lu, Shun
    Wang, Qun
    Ochi Lohmann, Tania
    Xu, Tingting
    Cardona, Andres
    Ruf, Thorsten
    Noe, Johannes
    Solomon, Benjamin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1265 - 1276
12345